Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts

American Journal of Transplantation

Volumn 7, Issue 3, 2007, Pages 576-585

  Haas, M ^a   Montgomery, R A ^a   Segev, D L ^a   Rahman, M H ^a   Racusen, L C ^a   Bagnasco, S M ^a   Simpkins, C E ^a   Warren, D S ^a   Lepley, D ^a   Zachary, A A ^a   Kraus, E S ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Accomodation; C4d; Chronic rejection; Protocol biopsy; Renal transplantation; Transplant glomerulopathy

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; CREATININE; CYTOMEGALOVIRUS ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CAPILLARY; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESENSITIZATION; DONOR; FEMALE; FOLLOW UP; GRAFT FAILURE; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; MALE; NEUTROPHIL CHEMOTAXIS; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES; COMPLEMENT C4B; CREATININE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA-A ANTIGENS; HUMANS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33847704587     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01657.x     Document Type: Article

References (40)

1. Ross CN, Gaskin G, Gregor-MacGregor S et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 1993; 55: 785-789.
2. Glotz D, Haymann J-P, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). Transplantation 1993; 56: 335-337.
3. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunogobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553-562.
4. Alarabi A, Backman U, Wikstrom B, Sjoberg O, Tufeson G. Pre-transplantation plasmapheresis in HLA-sensitized patients: Five years experience. Transplant Proc 1995: 27: 3448.
5. Higgins RM, Bevan DJ, Vaughan RW et al. 5-year follow-up of patients successfully transplanted after immunoadsorption to remove anti-HLA antibodies. Nephron 1996; 74: 53-57.
6. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
7. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023.
8. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519-1525.
9. Bohmig GA, Regele H, Exner M et al. C4d-positive acute humoral rejection: Effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482-2489.
10. Jordan SC, Quartel AW, Czer LSC et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
11. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334-341.
12. Mauiyyedi S, Della Pelle P, Saidman S et al. Chronic humoral rejection: Identification of antibody-mediated chronic allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
13. Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
14. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
15. Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129-2134.
16. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046-1052.
17. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 1-7.
18. Haas M, Rahman MH, Racusen LC et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840.
19. Haas M, Ratner LE, Montgomery RA. C4D staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711-717.
20. Collins AB, Schneeberger EE, Pascual M et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
21. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation 1996; 61: 1586-1592.
22. Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787.
23. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241.
24. Fidler ME, Gloor JM, Lager DJ et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004; 4: 101-107.
25. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
26. Koo DDH, Roberts ISD, Quiroga I et al. C4d deposition in early renal allograft protocol biopsies. Transplantation 2004; 78: 398-403.
27. Mengel M, Bogers J, Bosmans J-L et al. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 2005; 5: 1050-1056.
28. Platt JL. C4d and the fate of organ transplants. J Am Soc Nephrol 2002; 13: 2417-2419.
29. Park WD, Grande JP, Ninova D et al. Accomodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952-960.
30. Kanetsuna Y, Yamaguchi Y, Horita S, Tanabe K, Toma H. C4d and/or immunoglobulins deposition in peritubular capillaries in perioperative graft biopsies in ABO-incompatible renal transplantation. Clin Transplant 2004; 18 (Suppl 11): 13-17.
31. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78: 1471-1478.
32. Baldwin WM III, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER. Beyond C4d: Other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004; 4: 311-318.
33. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260-269.
34. Gloor JM, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donot kidney transplantation. Transplantation 2004; 78: 221-227.
35. Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847.
36. Nankivell BJ, Fenton-Lee CA, Kuypers DRJ et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523.
37. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
38. Nankivell BJ, Borrows RJ, Fung CL-S, O'Donnell PJ, Allen RDM, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-249.
39. Scholten EM, Rowshani AT, Cremers S et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17: 2622-2632.
40. Rush D. No benefit of protocol biopsies (PBx) in renal transplant patients (RTP) receiving tacrolimus (FK) and mycophenolate mofetil (MMF): A multicentre randomized study. World Transplant Congress Abstracts 2006; Abstract #843.